Trial Profile
Impact of LDL-cholesterol Lowering on Platelet Activation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 21 Jul 2020 Status changed from recruiting to discontinued. Reason the study was stopped: Terminated Prematurely due to COVID-19.
- 28 Jun 2019 Planned End Date changed from 1 Jun 2020 to 1 Nov 2021.
- 28 Jun 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2021.